Alteogen
Daejeon
About Alteogen
Founded in 2008, Alteogen is a leading bio company whose portfolio includes next-generation Biobetter, with improved efficacy in comparison with existing biologics, biosimilars that demonstrate “comparability” to the existing biologics, and proprietary biologics. Alteogen focus on the three cutting edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with complexity. Currently, Alteogen has developed NexP™ Fusion Technology, a next-generation long-acting biobetter technology on its own, developed NexMab™ ADC Technology, an Antibody-Drug Conjugate technology, novel human hyaluronidase PH 20 based on Hybrozyme Technology and is jointly developing Antibody Biosimilars with overseas strategic alliance partners.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2013)
- Website: alteogen.com
- Phone: +82-42-384-8780
Industries & Categories
Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/alteogen-49470 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.